logo
Share SHARE
FONT-SIZE Plus   Neg

Forest Labs., Gedeon Report Results From 2 Phase III Trials Of Cariprazine

Forest Laboratories, Inc. (FRX) and Gedeon Richter Plc announced positive top-line results in 2 Phase III clinical trials of cariprazine (RGH-188) for treating acute exacerbation of schizophrenia.

For the primary endpoint in each study, the Positive And Negative Syndrome Scale, the data showed that cariprazine-treated patients experienced significant symptom improvement compared to placebo-treated patients.

Besides, all doses showed statistically significant separation from placebo starting at week 2 and at each subsequent time point with the higher dose showing separation as early as week 1 of treatment. Further analyses of the data in each study will be completed in the coming weeks.

Forest Labs noted that the results of these 2 studies were consistent with the results of the previously completed placebo-controlled Phase IIb fixed-dose study in this population.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Stocks have moved mostly higher in early trading on Wednesday, adding to the gains posted in the previous session. The major averages have all climbed into positive territory, continuing to recover from Monday's sell-off. Venus and Jupiter, two old romantics in the night sky, danced last night after flirting all month. The two planets appeared so close they looked as though they were colliding. After reporting a sharp increase in U.S. construction spending in the previous month, the Commerce Department released a report on Wednesday showing that construction spending saw further upside in the month of May.
comments powered by Disqus
Follow RTT